BCAL Diagnostics (ASX: BDX) — Company Overview, News & Financial Data
BCAL Diagnostics is an Australian biotechnology company focused on developing and commercialising non-invasive blood tests for early cancer detection.
BCAL Diagnostics
BCAL Diagnostics is an Australian biotechnology company focused on developing and commercialising non-invasive blood tests for early cancer detection. The company's lead product, BREASTEST plus, is a lipid biomarker-based diagnostic test designed to complement mammography, particularly for women with dense breast tissue where imaging results may be inconclusive. In addition to breast cancer screening, BCAL Diagnostics is expanding its diagnostic technology pipeline into research programs for the early detection of pancreatic and ovarian cancers. The company collaborates with clinical specialists, medical practitioners, and accredited pathology partners across Australia to integrate its blood testing solutions into routine healthcare.
Snapshot
Operations
Products and/or services of BCAL Diagnostics
- Breast Cancer Blood Diagnostics: Development and commercialisation of non-invasive lipid biomarker blood tests designed to complement standard mammography screening, assisting medical practitioners in ruling out breast cancer in patients over age 30 with dense breast tissue.
- Pancreatic Cancer Diagnostic Research: Early-stage research and development program focused on identifying non-invasive blood-based biomarkers for the early detection of pancreatic cancer, aiming to expand diagnostic technology capabilities into additional high-fatality oncology indications.
- Ovarian Cancer Diagnostic Research: Research initiative applying lipidomic diagnostic platforms to identify circulating blood biomarkers for ovarian cancer, targeting early clinical detection and improved diagnostic precision to complement conventional clinical assessment tools.
- Clinical Pathology & Collection Services: Strategic coordination with accredited pathology laboratories, clinical specialists, and regional blood collection centers to process patient samples, conduct lipidomic biomarker evaluations, and deliver diagnostic results to healthcare providers.
BCAL Diagnostics executive team
- Ms. Jayne Andrea ShawCo-Founder & Executive Chairman
- Mr. Shane Ryan M.B.A.Chief Executive Officer
- Mr. Guy Adrian Robertson B.Com., B.Comm(Hons.), CA, MAICDCFO & Company Secretary
- Mr. Sean Alexander KennedyDirector of Corporate Finance
- Alexandra FeethamHead of Innovation
- Dr. Christopher Baldwin Ph.D.Chief Commercial Officer